600
Participants
Start Date
May 9, 2022
Primary Completion Date
December 23, 2026
Study Completion Date
December 23, 2026
Atectura inhalation capsule (150/80ug)
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
Atectura inhalation capsule (150/160ug)
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
Atectura inhalation capsule (150/320ug)
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
RECRUITING
Novartis Investigative Site, Goyang-si
ACTIVE_NOT_RECRUITING
Novartis Investigative Site, Wŏnju
COMPLETED
Novartis Investigative Site, Daejeon
RECRUITING
Novartis Investigative Site, Taegu
RECRUITING
Novartis Investigative Site, Daegu
RECRUITING
Novartis Investigative Site, Ulsan
RECRUITING
Novartis Investigative Site, Busan
RECRUITING
Novartis Investigative Site, Jeju City
COMPLETED
Novartis Investigative Site, Kangwon Do
COMPLETED
Novartis Investigative Site, Guri-si
RECRUITING
Novartis Investigative Site, Jeonju
RECRUITING
Novartis Investigative Site, Iksan Si
COMPLETED
Novartis Investigative Site, Gyeongsangnam Do
RECRUITING
Novartis Investigative Site, Jinju
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY